dividend stock

Bristol Myers Squibb's attractive 4.4% dividend yield faces headwinds from major patent expirations on blockbuster drugs Eliquis and Opdivo.

Strait of Hormuz disruptions threaten Coca-Cola with higher costs and currency headwinds, though its 63-year dividend streak suggests enduring resilience.

NextEra Energy leverages nuclear partnerships and 32-year dividend growth to capitalize on global atomic energy resurgence, targeting 8% EPS growth through 2035.

$ABT down 22% after disappointing earnings, but strong medical devices and $21B Exact Sciences deal offer recovery potential for income seekers.

Automatic Data Processing ($ADP) has fallen 36% amid AI concerns, but maintains strong dividend history with 51 consecutive annual increases, presenting potential value opportunity.

Walmart offers dividend investors growth through 24% e-commerce expansion and 37% ad growth, backed by 53 years of consecutive increases and a conservative 34% payout ratio.

Nike's stock has plummeted 50% since 2021 and fallen 11% in 2026, but CEO Elliott Hill's 'Win Now' turnaround strategy and reasonable valuation metrics suggest potential recovery for patient investors.

Coca-Cola's fortress brand and dividend growth appeal, but elevated 25.6 P/E valuation in a mature, slow-growth industry suggests limited five-year return potential.

Miller Value Partners exits entire $BKE position worth $4.2 million, citing weak earnings growth and near-zero projected 2027 profit expansion despite recent 36.8% stock gains.

Target surges 31% in three months on turnaround hopes, but faces headwinds with only 2% guidance. 3.8% dividend yield and Dividend King status appeal to income investors.

Hercules Capital insiders bought $1.9M in stock in February amid record $3.9B investment commitments and a fortress 120% dividend coverage ratio, signaling management confidence despite 52-week lows.

Mondelez trades down 10.6% despite posting 4% organic growth and 18% operating margins, offering a 3.32% yield with high-single-digit dividend growth potential.

$WMT shares fell 4.3% after Erste Group analyst downgraded stock to Hold, citing excessive 47x P/E valuation despite strong fundamentals.

Home Depot's strong Q4 earnings mask concerning fundamentals, with same-store sales at 0.3% and 26x valuation warranting a HOLD rating despite long-term tailwinds.

Middlesex Water director purchased 2,000 shares for $109K, signaling confidence. Stock up 10% in 2026 post-rate approval, offering 2.73% dividend yield with 114-year payment history.

ADP stock down 35% from highs amid labor market concerns, but company maintains strong fundamentals, dividend growth, and trades below historical valuation multiples.

Realty Income doubles investment pace to $8B target for 2026, exceeding 2025's $6.3B deployment through acquisitions, partnerships, and European expansion.

Abbott maintains 54-year dividend streak with 10% EPS growth projected for 2026, despite near-term diagnostic headwinds and manufacturing challenges offsetting strategic acquisitions and FDA approvals.

Enbridge authorizes CA$14B in 2025 capital projects with CA$39B backlog through 2033, supporting 5% annual earnings growth and consistent dividend increases.

Medtronic offers defensive stability through 48 years of dividend increases, essential medical devices, and consistent profitability across economic cycles.